These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22658528)

  • 21. Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol.
    Riedel M; Mayr A; Seemüller F; Maier W; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Schmitt A; Sauer H; Schneider F; Gaebel W; Jäger M; Möller HJ; Schennach-Wolff R
    World J Biol Psychiatry; 2012 Jan; 13(1):30-8. PubMed ID: 21568628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
    Schennach-Wolff R; Jäger M; Obermeier M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Seemüller F; Möller HJ; Riedel M
    World J Biol Psychiatry; 2010 Aug; 11(5):729-38. PubMed ID: 20380620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders.
    Schennach-Wolff R; Jäger M; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Huff W; Heuser I; Maier W; Lemke MR; Rüther E; Buchkremer G; Gastpar M; Möller HJ; Riedel M
    Schizophr Res; 2009 Sep; 113(2-3):210-7. PubMed ID: 19560901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.
    Heres S; Don L; Herceg M; Bidzan L; Blanc M; Siracusano A; Maciulis V; Lahaye M; Schreiner A
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():207-12. PubMed ID: 24096139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs.
    Mauri MC; Moliterno D; Rossattini M; Colasanti A
    Schizophr Res; 2008 Feb; 99(1-3):7-12. PubMed ID: 18055177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia.
    Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Zhou W; Kapur S; Kane JM; Naber D
    Schizophr Res; 2010 May; 118(1-3):176-82. PubMed ID: 20080036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study.
    Guo X; Zhai J; Wei Q; Twamley EW; Jin H; Fang M; Hu M; Zhao J;
    Neurosci Lett; 2011 Oct; 503(2):141-6. PubMed ID: 21888948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlates, change and 'state or trait' properties of insight in schizophrenia.
    Wiffen BD; Rabinowitz J; Lex A; David AS
    Schizophr Res; 2010 Sep; 122(1-3):94-103. PubMed ID: 20382507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. One-year outcome and its prediction in first-episode schizophrenia--a naturalistic study.
    Bachmann S; Bottmer C; Schroder J
    Psychopathology; 2008; 41(2):115-23. PubMed ID: 18059113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [RÉALITÉ LT, a pharmacoepidemiological study of semiology and therapeutic strategy of patients with schizophrenia treated by antipsychotic loxapine in routine clinical practice].
    Cousin FR; Samuelian JC; Saoud M; Schmitt L; Vacheron MN; Vidailhet P; Augendre J; Walter M; Tonelli I; Pascal JC
    Encephale; 2012 Feb; 38(1):64-74. PubMed ID: 22381726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach.
    Lipkovich IA; Deberdt W; Csernansky JG; Buckley P; Peuskens J; Kollack-Walker S; Rotelli M; Houston JP
    Psychiatry Res; 2009 Dec; 170(2-3):161-7. PubMed ID: 19897252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year functional outcomes of naturalistically treated patients with schizophrenia.
    Spellmann I; Riedel M; Schennach R; Seemüller F; Obermeier M; Musil R; Jäger M; Schmauß M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ
    Psychiatry Res; 2012 Aug; 198(3):378-85. PubMed ID: 22421065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia.
    Lewis SW; Barnes TR; Davies L; Murray RM; Dunn G; Hayhurst KP; Markwick A; Lloyd H; Jones PB
    Schizophr Bull; 2006 Oct; 32(4):715-23. PubMed ID: 16540702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of clozapine use in delaying hospitalization in routine clinical practice: a 2 year observational study.
    Nyakyoma K; Morriss R
    Psychopharmacol Bull; 2010; 43(2):67-81. PubMed ID: 21052043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment.
    Li M; Chen Z; Deng W; He Z; Wang Q; Jiang L; Ma X; Wang Y; Chua SE; Cheung C; McAlonan GM; Sham PC; Collier DA; Gong Q; Li T
    Psychol Med; 2012 Jul; 42(7):1475-83. PubMed ID: 22030695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients.
    Szymanski S; Lieberman JA; Alvir JM; Mayerhoff D; Loebel A; Geisler S; Chakos M; Koreen A; Jody D; Kane J
    Am J Psychiatry; 1995 May; 152(5):698-703. PubMed ID: 7726309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.
    Robinson DG; Woerner MG; Alvir JM; Geisler S; Koreen A; Sheitman B; Chakos M; Mayerhoff D; Bilder R; Goldman R; Lieberman JA
    Am J Psychiatry; 1999 Apr; 156(4):544-9. PubMed ID: 10200732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing symptom response among antipsychotic medications in CATIE.
    Levine SZ; Rabinowitz J; Ascher-Svanum H; Faries DE; Lawson AH
    J Clin Psychopharmacol; 2013 Feb; 33(1):123-6. PubMed ID: 23288232
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.